MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jacig.2026.100705

Медицинская библиотека · The journal of allergy and clinical immunology. Global · 2026

Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East.

Elkhalifa Shuayb, Mahmoud Eiman, Salvo Fulvio, AlHameli Hamad, Cerecedo Inmaculada, Shafiq Irfan, Abuzakouk Mohamed

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Chronic spontaneous urticaria (CSU) is a mast cell-mediated condition that can cause significant impairment in quality of life. Second-generation H1-antihistamines are recommended as first-line treatment, but a proportion of patients do not achieve adequate control and require add-on therapy. Omalizumab is the preferred biologic for CSU that is unresponsive to high-dose H1-antihistamines.

OBJECTIVE

Our aim was to assess the efficacy and safety of omalizumab in patients with CSU refractory to high-dose second-generation H1-antihistamines within a Middle Eastern tertiary care health care setting and to then relate the findings to current international urticaria guideline recommendations.

METHODS

A retrospective observational study was undertaken at a tertiary allergy clinic from September 2015 to September 2018. A total of 75 adults with CSU of more than 6 months' duration and unresponsive to 4-fold doses of H1-antihistamines received omalizumab and were followed in the clinic. The primary outcome was change in Urticaria Control Test score before and after treatment. Additional data included responder classification, comorbidities, laboratory findings, treatment intervals, and adverse events.

RESULTS

There was a significant improvement in Urticaria Control Test score following omalizumab treatment (mean change -7.56; P < .001), with no association between outcome and baseline IgE levels. The response rates were 84% complete, 13% partial, and 3% poor. Most complete responders achieved control after 1 or 2 doses. Vitamin D deficiency and raised IgE level were frequent but did not predict response. Adverse events were infrequent and mild.

CONCLUSION

Omalizumab is effective and well tolerated in CSU that is refractory to high-dose H1-antihistamines, providing rapid and sustained symptom control in most patients. Current international guidelines continue to recommend omalizumab as the first-choice add-on therapy in this setting, with other biologics remaining under investigation.

Для цитирования: Elkhalifa Shuayb, Mahmoud Eiman, Salvo Fulvio, AlHameli Hamad, Cerecedo Inmaculada, Shafiq Irfan, Abuzakouk Mohamed. Real-world efficacy and safety of omalizumab in chronic spontaneous urticaria: Insights from the Middle East.. The journal of allergy and clinical immunology. Global. 2026. DOI: 10.1016/j.jacig.2026.100705.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.